Study S000535

Impact of Liraglutide on Cardiac Function and Structure in Young Adults With Type 2 Diabetes: an Open-label, Randomised Active-comparator Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02043054
Acronym: LYDIA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 90
Start: 2013-12-16
Primary completion: 2017-09-02
Lead sponsor: University of Leicester
Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease
Interventions: DRUG:Liraglutide; DRUG:Sitagliptin
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2012-002422-78; REGISTRY:U1111-1131-8802

Registered primary outcomes

Change in peak early diastolic strain rate measured by cardiac MRI [Change from baseline peak end diastolic strain rate at 26 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0038889	MRI Assessment of Subclinical Cardiac Dysfunction and its Association With Ectopic Fat in Adults With Type 2 Diabetes Althagafi, Loai K., University of Leicester	2023	Randomized trial	DOI	cites ClinicalTrials.gov:NCT02043054
R0019476	Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study). Htike ZZ, Cardiovascular diabetology	2016	Protocol	PMID 27440110 DOI	cites ClinicalTrials.gov:NCT02043054; registry reference DERIVED:27440110